Biogen's aducanumab/Aduhelm is a medication designed to treat Alzheimer's disease. It was approved for medical use in the United States by the Food and Drug Administration (FDA) in June 2021, in a controversial decision that led to the resignation of three advisers to the FDA in the absence of evidence that the drug is effective. Aducanumab was rejected for medical use in Europe in December 2021 by the European Medicines Agency (EMA).

In May 2022, two researchers published a commentary in the Journal of Alzheimer's Disease, asking for aducanumab to be immediately withdrawn, citing the lack of demonstrated benefit to patients and major concerns about safety, FDA processes, and regulatory capture by Biogen.

The question resolves as YES as soon as the FDA announces the withdrawal of aducanumab/Aduhelm.